In October 2017, Incyte entered into a global collaboration and license agreement with us in which they obtained exclusive worldwide rights for the development and commercialization of MGA012, an anti-PD-1 antibody, in all indications. In addition to receiving an upfront payment, MacroGenics is eligible to receive milestones and royalties and retains the right to develop its pipeline assets in combination with MGA012. Learn more
Collaborations have been a critical part of MacroGenics’ growth strategy and will continue to be an emphasis for our future growth strategy. To date, the company has developed significant alliances with leading pharmaceutical and biotechnology companies that enable us to drive forward our proprietary programs, while retaining significant value in the downstream potential of our partnered programs.
The company is actively exploring alliances that complement our expertise in biologics product development with important scientific, clinical and business capabilities. These alliances may incorporate our various technology platforms, product candidates and biologic product development capabilities.
MacroGenics’ Collaboration Partners
In November 2018, we announced that Zai Lab had entered into an exclusive collaboration and license agreement with us for regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan for margetuximab, MGD013 and an undisclosed multi-specific TRIDENT™ molecule in preclinical development. Learn more
In July 2019, we announced that I-Mab Biopharma had entered into an exclusive collaboration and license agreement with us for regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan for enoblituzumab. Learn more
In July 2010, GC Pharma (formerly Green Cross) entered into a collaboration agreement with MacroGenics for the development and exclusive commercialization of margetuximab in South Korea.
In September 2015, MacroGenics entered into a contract with the National Institute of Allergy and Infectious Diseases to perform product development and to advance DART product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with HIV infection (contract no. HHSN272201500032C). Learn more